← Back to Company DatabaseVisit Website
Delfi Diagnostics
Fragmentomics-based liquid biopsy for early cancer detection.
Series BBaltimore, MDFounded 2019
About
Delfi Diagnostics is developing a novel approach to cancer detection using cell-free DNA fragmentation patterns, known as fragmentomics. The technology analyzes how DNA from cancer cells breaks apart differently than normal DNA, enabling earlier and more affordable cancer detection. The company's DELFI approach originated from research at Johns Hopkins University.
Total Funding
$350MKey Product
FirstLook Lung cancer screening testGeography
North AmericaKey Investors
Third Rock Venturesa16z BioArch Venture Partners
Focus Areas
Early Detection / ScreeningDiagnostics
Technology
Liquid BiopsyGenomics / SequencingAI / Machine Learning
Cancer Types
LungPan-cancer
Last updated: Feb 4, 2026